Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-004165-41-GB (EUCTR)	04/11/2013	19/09/2013	Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - Hematopoietic Stem Cell Therapy for Inflammatory MS	Inflammatory Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri Product Name: Tysabri INN or Proposed INN: natalizumab Trade Name: Fingolimod Product Name: Gilenya INN or Proposed INN: Fingolimod Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG-12 120 INN or Proposed INN: dimethyl fumarate	Northwestern University	NULL	Not Recruiting			Female: yes Male: yes	110	Phase 2	United States;United Kingdom
2	NCT03133403 (ClinicalTrials.gov)	November 2013	21/4/2016	Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Tecfidera (BG12);Drug: Gilenya;Drug: Tysabri ®;Drug: Avonex /Betaseron/Copaxone/Rebif;Procedure: Hematopoietic stem cell transplantation (HSCT)	Sheffield Teaching Hospitals NHS Foundation Trust	NULL	Recruiting	18 Years	55 Years	All	5	Phase 2/Phase 3	United Kingdom
3	NCT00273364 (ClinicalTrials.gov)	November 16, 2005	5/1/2006	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Multiple Sclerosis	Procedure: Hematopoietic Stem Cell Therapy;Drug: Standard treatment with a conventional drug	Northwestern University	Uppsala University;Sheffield Teaching Hospitals NHS Foundation Trust;University of Sao Paulo	Completed	18 Years	55 Years	All	110	Phase 2	United States
4	NCT00278655 (ClinicalTrials.gov)	June 2003	16/1/2006	Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial	Multiple Sclerosis	Biological: Hematopoietic stem cell transplantation	Northwestern University	NULL	Terminated	18 Years	50 Years	All	21	Phase 1/Phase 2	United States